- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
- Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
- Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
- Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
- Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
- Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
- Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
- Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
- Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
- Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
More ▼
Key statistics
On Monday, Sagimet Biosciences Inc (SGMT:NMQ) closed at 4.28, 100.94% above the 52 week low of 2.13 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.38 |
---|---|
High | 4.56 |
Low | 4.16 |
Bid | 4.29 |
Offer | 4.35 |
Previous close | 4.32 |
Average volume | 497.39k |
---|---|
Shares outstanding | 31.92m |
Free float | 26.04m |
P/E (TTM) | -- |
Market cap | 137.87m USD |
EPS (TTM) | -1.31 USD |
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
More ▼